‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...
Hims & Hers Zepbound Offering Won’t Bring Needed Sales Boom, Analysts Say
Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...
Hims to Sell Lilly’s Zepbound Through Telehealth Platform
Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to ...
Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings
Hims & Hers Health (NYSE:HIMS) recently experienced a 5% price increase over the past quarter, marked by significant corporate events. The company was added to the S&P 400 index and simultaneously ...
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own ...
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...